VANDA PHARMACEUTICALS INC. Research and Development Expense
VANDA PHARMACEUTICALS INC. (VNDA) reported Research and Development Expense of $36.95 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- VANDA PHARMACEUTICALS INC. research and development expense for the quarter ending 2026-06-30 was $36.95M, a 68.04% increase year-over-year.
- VANDA PHARMACEUTICALS INC. research and development expense for the quarter ending 2026-03-31 was $28.43M, a 20.38% decline year-over-year.
- VANDA PHARMACEUTICALS INC. research and development expense for the quarter ending 2025-12-31 was $29.01M, a 46.20% increase year-over-year.
- VANDA PHARMACEUTICALS INC. research and development expense for the quarter ending 2025-09-30 was $22.56M, a 34.50% increase year-over-year.
- VANDA PHARMACEUTICALS INC. research and development expense for fiscal 2025 was $109.27M, a 46.81% increase from fiscal 2024.
- VANDA PHARMACEUTICALS INC. research and development expense for fiscal 2024 was $74.43M, a 3.11% decline from fiscal 2023.
- VANDA PHARMACEUTICALS INC. research and development expense for fiscal 2023 was $76.82M, a 10.43% decline from fiscal 2022.
- VANDA PHARMACEUTICALS INC. research and development expense for fiscal 2022 was $85.77M, a 13.81% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $36.95M 10-Q · filed 2026-08-06 | $65.39M 10-Q · filed 2026-08-06 | $94.39M derived: sum of 3 quarters · filed 2026-08-06 | $116.96M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $28.43M 10-Q · filed 2026-05-07 | $57.44M derived: sum of 2 quarters · filed 2026-05-07 | $80.00M derived: sum of 3 quarters · filed 2026-05-07 | $101.99M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $29.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $51.57M derived: sum of 2 quarters · filed 2026-02-12 | $73.56M derived: sum of 3 quarters · filed 2026-08-06 | $109.27M 10-K · filed 2026-02-12 | ||||
| 2025-09-30 | $22.56M 10-Q · filed 2025-10-30 | $44.55M derived: sum of 2 quarters · filed 2026-08-06 | $80.27M 10-Q · filed 2025-10-30 | $100.11M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $21.99M 10-Q · filed 2026-08-06 | $57.70M 10-Q · filed 2026-08-06 | $77.54M derived: sum of 3 quarters · filed 2026-08-06 | $94.32M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $35.71M 10-Q · filed 2026-05-07 | $55.55M derived: sum of 2 quarters · filed 2026-05-07 | $72.33M derived: sum of 3 quarters · filed 2026-05-07 | $88.99M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $19.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $36.62M derived: sum of 2 quarters · filed 2026-02-12 | $53.28M derived: sum of 3 quarters · filed 2026-02-12 | $74.43M 10-K · filed 2026-02-12 | ||||
| 2024-09-30 | $16.78M 10-Q · filed 2025-10-30 | $33.44M derived: sum of 2 quarters · filed 2025-10-30 | $54.59M 10-Q · filed 2025-10-30 | $78.93M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-06-30 | $16.66M 10-Q · filed 2025-07-31 | $37.81M 10-Q · filed 2025-07-31 | $62.15M derived: sum of 3 quarters · filed 2026-02-12 | $78.75M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-03-31 | $21.15M 10-Q · filed 2025-05-08 | $45.49M derived: sum of 2 quarters · filed 2026-02-12 | $62.09M derived: sum of 3 quarters · filed 2026-02-12 | $78.74M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2023-12-31 | $24.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $40.94M derived: sum of 2 quarters · filed 2026-02-12 | $57.59M derived: sum of 3 quarters · filed 2026-02-12 | $76.82M 10-K · filed 2026-02-12 | ||||
| 2023-09-30 | $16.60M 10-Q · filed 2024-11-07 | $33.25M derived: sum of 2 quarters · filed 2024-11-07 | $52.48M 10-Q · filed 2024-11-07 | $70.94M derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-06-30 | $16.65M 10-Q · filed 2024-08-01 | $35.88M 10-Q · filed 2024-08-01 | $54.34M derived: sum of 3 quarters · filed 2025-02-14 | $79.19M derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-03-31 | $19.24M 10-Q · filed 2024-05-09 | $37.69M derived: sum of 2 quarters · filed 2025-02-14 | $62.55M derived: sum of 3 quarters · filed 2025-02-14 | $84.04M derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2022-12-31 | $18.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $43.31M derived: sum of 2 quarters · filed 2025-02-14 | $64.80M derived: sum of 3 quarters · filed 2025-02-14 | $85.77M 10-K · filed 2025-02-14 | ||||
| 2022-09-30 | $24.86M 10-Q · filed 2023-11-09 | $46.35M derived: sum of 2 quarters · filed 2023-11-09 | $67.32M 10-Q · filed 2023-11-09 | $86.65M derived: sum of 4 quarters · filed 2024-02-08 | ||||
| 2022-06-30 | $21.49M 10-Q · filed 2023-07-28 | $42.46M 10-Q · filed 2023-07-28 | $61.79M derived: sum of 3 quarters · filed 2024-02-08 | $81.44M derived: sum of 4 quarters · filed 2024-02-08 | ||||
| 2022-03-31 | $20.97M 10-Q · filed 2023-05-03 | $40.30M derived: sum of 2 quarters · filed 2024-02-08 | $59.95M derived: sum of 3 quarters · filed 2024-02-08 | $80.20M derived: sum of 4 quarters · filed 2024-02-08 | ||||
| 2021-12-31 | $19.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-08 | $38.98M derived: sum of 2 quarters · filed 2024-02-08 | $59.23M derived: sum of 3 quarters · filed 2024-02-08 | $75.36M 10-K · filed 2024-02-08 | ||||
| 2021-09-30 | $19.65M 10-Q · filed 2022-11-03 | $39.90M derived: sum of 2 quarters · filed 2022-11-03 | $56.03M 10-Q · filed 2022-11-03 | $70.88M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-06-30 | $20.25M 10-Q · filed 2022-08-04 | $36.38M 10-Q · filed 2022-08-04 | $51.23M derived: sum of 3 quarters · filed 2023-02-09 | $63.53M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2021-03-31 | $16.13M 10-Q · filed 2022-05-06 | $30.98M derived: sum of 2 quarters · filed 2023-02-09 | $43.28M derived: sum of 3 quarters · filed 2023-02-09 | $56.18M derived: sum of 4 quarters · filed 2023-02-09 | ||||
| 2020-12-31 | $14.85M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | $27.15M derived: sum of 2 quarters · filed 2023-02-09 | $40.05M derived: sum of 3 quarters · filed 2023-02-09 | $55.58M 10-K · filed 2023-02-09 | ||||
| 2020-09-30 | $12.30M 10-Q · filed 2021-11-04 | $25.20M derived: sum of 2 quarters · filed 2021-11-04 | $40.73M 10-Q · filed 2021-11-04 | $53.80M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-06-30 | $12.90M 10-Q · filed 2021-07-29 | $28.43M 10-Q · filed 2021-07-29 | $41.50M derived: sum of 3 quarters · filed 2022-02-24 | $52.85M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2020-03-31 | $15.53M 10-Q · filed 2021-05-06 | $28.60M derived: sum of 2 quarters · filed 2022-02-24 | $39.95M derived: sum of 3 quarters · filed 2022-02-24 | $50.90M derived: sum of 4 quarters · filed 2022-02-24 | ||||
| 2019-12-31 | $13.07M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $24.42M derived: sum of 2 quarters · filed 2022-02-24 | $35.37M derived: sum of 3 quarters · filed 2022-02-24 | $48.65M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $11.35M 10-Q · filed 2020-10-29 | $22.30M derived: sum of 2 quarters · filed 2020-10-29 | $35.58M 10-Q · filed 2020-10-29 | $48.50M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-06-30 | $10.95M 10-Q · filed 2020-08-06 | $24.23M 10-Q · filed 2020-08-06 | $37.15M derived: sum of 3 quarters · filed 2021-02-11 | $48.54M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2019-03-31 | $13.28M 10-Q · filed 2020-05-07 | $26.20M derived: sum of 2 quarters · filed 2021-02-11 | $37.59M derived: sum of 3 quarters · filed 2021-02-11 | $47.46M derived: sum of 4 quarters · filed 2021-02-11 | ||||
| 2018-12-31 | $12.92M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-11 | $24.31M derived: sum of 2 quarters · filed 2021-02-11 | $34.18M derived: sum of 3 quarters · filed 2021-02-11 | $43.59M 10-K · filed 2021-02-11 | ||||
| 2018-09-30 | $11.39M 10-Q · filed 2019-11-07 | $21.26M derived: sum of 2 quarters · filed 2019-11-07 | $30.67M 10-Q · filed 2019-11-07 | $40.83M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-06-30 | $9.87M 10-Q · filed 2019-08-01 | $19.28M 10-Q · filed 2019-08-01 | $29.44M derived: sum of 3 quarters · filed 2020-02-26 | $39.61M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-03-31 | $9.42M 10-Q · filed 2019-05-03 | $19.57M derived: sum of 2 quarters · filed 2020-02-26 | $29.75M derived: sum of 3 quarters · filed 2020-02-26 | $37.40M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | $10.15M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $20.33M derived: sum of 2 quarters · filed 2020-02-26 | $27.98M derived: sum of 3 quarters · filed 2020-02-26 | $38.55M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $10.18M 10-Q · filed 2018-11-07 | $17.83M derived: sum of 2 quarters · filed 2018-11-07 | $28.39M 10-Q · filed 2018-11-07 | $36.01M derived: sum of 4 quarters · filed 2019-02-19 | ||||
| 2017-06-30 | $7.65M 10-Q · filed 2018-08-02 | $18.21M 10-Q · filed 2018-08-02 | $25.83M derived: sum of 3 quarters · filed 2019-02-19 | $33.12M derived: sum of 4 quarters · filed 2019-02-19 | ||||
| 2017-03-31 | $10.57M 10-Q · filed 2018-05-02 | $18.18M derived: sum of 2 quarters · filed 2019-02-19 | $25.48M derived: sum of 3 quarters · filed 2019-02-19 | $32.17M derived: sum of 4 quarters · filed 2019-02-19 | ||||
| 2016-12-31 | $7.61M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $14.91M derived: sum of 2 quarters · filed 2019-02-19 | $21.61M derived: sum of 3 quarters · filed 2019-02-19 | $29.16M 10-K · filed 2019-02-19 | ||||
| 2016-09-30 | $7.29M 10-Q · filed 2017-11-08 | $13.99M derived: sum of 2 quarters · filed 2017-11-08 | $21.54M 10-Q · filed 2017-11-08 | $30.29M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-06-30 | $6.70M 10-Q · filed 2017-08-03 | $14.25M 10-Q · filed 2017-08-03 | $23.00M derived: sum of 3 quarters · filed 2018-02-15 | $32.97M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2016-03-31 | $7.55M 10-Q · filed 2017-05-03 | $16.30M derived: sum of 2 quarters · filed 2018-02-15 | $26.27M derived: sum of 3 quarters · filed 2018-02-15 | $32.22M derived: sum of 4 quarters · filed 2018-02-15 | ||||
| 2015-12-31 | $8.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $18.72M derived: sum of 2 quarters · filed 2018-02-15 | $24.67M derived: sum of 3 quarters · filed 2018-02-15 | $29.14M 10-K · filed 2018-02-15 | ||||
| 2015-09-30 | $9.97M 10-Q · filed 2016-11-03 | $15.92M derived: sum of 2 quarters · filed 2016-11-03 | $20.40M 10-Q · filed 2016-11-03 | $25.15M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-06-30 | $5.95M 10-Q · filed 2016-07-28 | $10.42M 10-Q · filed 2016-07-28 | $15.18M derived: sum of 3 quarters · filed 2017-02-17 | $18.88M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | $4.48M 10-Q · filed 2016-05-05 | $9.23M derived: sum of 2 quarters · filed 2017-02-17 | $12.93M derived: sum of 3 quarters · filed 2017-02-17 | $16.44M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2014-12-31 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $8.45M derived: sum of 2 quarters · filed 2017-02-17 | $11.97M derived: sum of 3 quarters · filed 2017-02-17 | $19.23M 10-K · filed 2017-02-17 | ||||
| 2014-09-30 | $3.70M 10-Q · filed 2015-11-04 | $7.21M derived: sum of 2 quarters · filed 2015-11-04 | $14.48M 10-Q · filed 2015-11-04 | $20.75M derived: sum of 4 quarters · filed 2016-02-12 | ||||
| 2014-06-30 | $3.51M 10-Q · filed 2015-07-31 | $10.78M 10-Q · filed 2015-07-31 | $17.05M derived: sum of 3 quarters · filed 2016-02-12 | $25.07M derived: sum of 4 quarters · filed 2016-02-12 | ||||
| 2014-03-31 | $7.26M 10-Q · filed 2015-05-07 | $13.53M derived: sum of 2 quarters · filed 2016-02-12 | $21.55M derived: sum of 3 quarters · filed 2016-02-12 | $27.65M derived: sum of 4 quarters · filed 2016-02-12 | ||||
| 2013-12-31 | $6.27M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $14.29M derived: sum of 2 quarters · filed 2016-02-12 | $20.39M derived: sum of 3 quarters · filed 2016-02-12 | $28.50M 10-K · filed 2016-02-12 | $28.19M 10-K · filed 2014-02-25 | |||
| 2013-09-30 | $8.02M 10-Q · filed 2014-10-27 | $8.03M 10-Q · filed 2013-11-08 | $14.12M derived: sum of 2 quarters · filed 2014-10-27 | $22.23M 10-Q · filed 2014-10-27 | $21.97M 10-Q · filed 2013-11-08 | $33.17M derived: sum of 4 quarters · filed 2015-03-13 | ||
| 2013-06-30 | $6.10M 10-Q · filed 2014-08-08 | $5.98M 10-Q · filed 2013-07-31 | $14.21M 10-Q · filed 2014-08-08 | $13.94M 10-Q · filed 2013-07-31 | $25.15M derived: sum of 3 quarters · filed 2015-03-13 | $35.30M derived: sum of 4 quarters · filed 2015-03-13 | ||
| 2013-03-31 | $8.11M 10-Q · filed 2014-05-08 | $7.96M 10-Q · filed 2013-05-10 | $19.05M derived: sum of 2 quarters · filed 2015-03-13 | $29.20M derived: sum of 3 quarters · filed 2015-03-13 | $41.70M derived: sum of 4 quarters · filed 2015-03-13 | |||
| 2012-12-31 | $10.94M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $21.09M derived: sum of 2 quarters · filed 2015-03-13 | $33.58M derived: sum of 3 quarters · filed 2015-03-13 | $45.76M 10-K · filed 2015-03-13 | $45.45M 10-K · filed 2013-02-26 | |||
| 2012-09-30 | $10.16M 10-Q · filed 2013-11-08 | $22.65M derived: sum of 2 quarters · filed 2013-11-08 | $34.83M 10-Q · filed 2013-11-08 | $45.38M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $12.49M 10-Q · filed 2013-07-31 | $24.67M 10-Q · filed 2013-07-31 | $35.23M derived: sum of 3 quarters · filed 2014-02-25 | $43.40M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $12.18M 10-Q · filed 2013-05-10 | $22.74M derived: sum of 2 quarters · filed 2014-02-25 | $30.91M derived: sum of 3 quarters · filed 2014-02-25 | $36.91M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $10.56M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $18.73M derived: sum of 2 quarters · filed 2014-02-25 | $24.73M derived: sum of 3 quarters · filed 2014-02-25 | $29.00M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $8.17M 10-Q · filed 2012-11-08 | $14.17M derived: sum of 2 quarters · filed 2012-11-08 | $18.44M 10-Q · filed 2012-11-08 | $22.26M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $6.00M 10-Q · filed 2012-08-03 | $10.27M 10-Q · filed 2012-08-03 | $14.09M derived: sum of 3 quarters · filed 2013-02-26 | $18.16M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $4.27M 10-Q · filed 2012-05-09 | $8.09M derived: sum of 2 quarters · filed 2013-02-26 | $12.16M derived: sum of 3 quarters · filed 2013-02-26 | $14.56M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $3.82M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $7.89M derived: sum of 2 quarters · filed 2013-02-26 | $10.30M derived: sum of 3 quarters · filed 2013-02-26 | $12.34M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | $4.07M 10-Q · filed 2011-11-07 | $6.47M derived: sum of 2 quarters · filed 2011-11-07 | $8.52M 10-Q · filed 2011-11-07 | |||||
| 2010-06-30 | $2.40M 10-Q · filed 2011-08-05 | $4.44M 10-Q · filed 2011-08-05 | ||||||
| 2009-12-31 | $13.87M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |